Wyniki badania ADVANCE (The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation)

The ADVANCE Collaborative Group – Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Published at www.nejm.org June 6, 2008 (10.1056/NEJMoa0802987)

Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925 [ClinicalTrials.gov] .)

Opracowane na podstawie: Published at www.nejm.org June 6, 2008 (10.1056/NEJMoa0802987)/ 2008-06-06